Plasma β-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy
暂无分享,去创建一个
Eric E. Smith | Ramon Diaz-Arrastia | Jonathan Rosand | Steven M. Greenberg | J. Growdon | S. Greenberg | M. Irizarry | R. Diaz-Arrastia | J. Rosand | J. Rosand | T. Bottiglieri | M. Gurol | Susan Raju | Michael C. Irizarry | J. H. Growdon | Teodoro Bottiglieri | S. Raju | Mahmut E. Gurol | E. Smith | E. E. Smith | T. Bottiglieri | S. Greenberg
[1] J. Growdon,et al. Association of homocysteine with plasma amyloid β protein in aging and neurodegenerative disease , 2005, Neurology.
[2] Karen J. Ferguson,et al. Intracranial area: a validated method for estimating intracranial volume. , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[3] S. Greenberg,et al. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage , 2004, Neurology.
[4] M. Citron,et al. Strategies for disease modification in Alzheimer's disease , 2004, Nature Reviews Neuroscience.
[5] A. Hofman,et al. Plasma amyloid β, apolipoprotein E, lacunar infarcts, and white matter lesions , 2004, Annals of neurology.
[6] K. Blennow,et al. Plasma Levels of β-Amyloid(1-40), β-Amyloid(1-42), and Total β-Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins , 2004 .
[7] C. Iadecola,et al. Aβ-Induced Vascular Oxidative Stress and Attenuation of Functional Hyperemia in Mouse Somatosensory Cortex , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[8] F. Faraci,et al. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. , 2004, Stroke.
[9] K. Blennow,et al. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. , 2004, Archives of neurology.
[10] J. Carr,et al. Plasma total homocysteine levels and cranial magnetic resonance imaging findings in elderly persons: the Cardiovascular Health Study. , 2004, Archives of neurology.
[11] John Breitner,et al. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. , 2003, Archives of neurology.
[12] J. Growdon,et al. Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels , 2003 .
[13] Ann Marie Schmidt,et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.
[14] A. Hofman,et al. Silent brain infarcts and the risk of dementia and cognitive decline. , 2003, The New England journal of medicine.
[15] J. Growdon,et al. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. , 2003, Archives of neurology.
[16] Theo Gasser,et al. Assessing intrarater, interrater and test–retest reliability of continuous measurements , 2002, Statistics in medicine.
[17] S. Younkin,et al. Serum creatinine levels correlate with plasma amyloid β protein , 2002 .
[18] S. Younkin,et al. Serum Creatinine Levels Correlate With Plasma Amyloid &bgr; Protein , 2002, Alzheimer disease and associated disorders.
[19] A. Smith,et al. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. , 2002, Archives of neurology.
[20] D. Holtzman,et al. Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease , 2002, Science.
[21] Matthijs Oudkerk,et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam scan study , 2002, Annals of neurology.
[22] M. Mattson,et al. Folic Acid Deficiency and Homocysteine Impair DNA Repair in Hippocampal Neurons and Sensitize Them to Amyloid Toxicity in Experimental Models of Alzheimer's Disease , 2002, The Journal of Neuroscience.
[23] Sudha Seshadri,et al. Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease , 2002 .
[24] E. Tangalos,et al. CME Practice parameter: , 2022 .
[25] S. Greenberg,et al. Clinical diagnosis of cerebral amyloid angiopathy: Validation of the Boston Criteria , 2003, Current atherosclerosis reports.
[26] George A. Carlson,et al. Exogenous Aβ1–40 Reproduces Cerebrovascular Alterations Resulting from Amyloid Precursor Protein Overexpression in Mice , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[27] A. Hofman,et al. Cerebral white matter lesions and depressive symptoms in elderly adults. , 2000, Archives of general psychiatry.
[28] C. Iadecola,et al. Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[29] S. Younkin,et al. Plasma β‐Amyloid Peptide, Transforming Growth Factor‐β1, and Risk for Cerebral Amyloid Angiopathy , 2000 .
[30] A. Hofman,et al. Cerebral white matter lesions and cognitive function: The Rotterdam scan study , 2000, Annals of neurology.
[31] K. Furie,et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. , 2000, The New England journal of medicine.
[32] S. Oparil,et al. Essential Hypertension : Part I : Definition and Etiology , 1999 .
[33] S. Younkin,et al. Plasma beta-amyloid peptide, transforming growth factor-beta 1, and risk for cerebral amyloid angiopathy. , 2000, Annals of the New York Academy of Sciences.
[34] R. Mohs,et al. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease , 1998, Neurology.
[35] Elisabet Englund,et al. Neuropathology of White Matter Changes in Alzheimer’s Disease and Vascular Dementia , 1998, Dementia and Geriatric Cognitive Disorders.
[36] S. Greenberg,et al. Association of apolipoprotein E ϵ2 and vasculopathy in cerebral amyloid angiopathy , 1998, Neurology.
[37] B. Hyman,et al. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. , 1998, Neurology.
[38] G C Roman,et al. Brain infarction and the clinical expression of Alzheimer disease. , 1997, JAMA.
[39] D. Graham,et al. High frequency of apolipoprotein E ϵ2 Allele in hemorrhage due to cerebral amyloid angiopathy , 1997, Annals of neurology.
[40] W. Markesbery,et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.
[41] L. Fried,et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. , 1996, Stroke.
[42] M. Mullan,et al. β-Amyloid-mediated vasoactivity and vascular endothelial damage , 1996, Nature.
[43] M. Mullan,et al. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. , 1996, Nature.
[44] N. Inestrosa,et al. Platelets Are the Primary Source of Amyloid β-Peptide in Human Blood , 1995 .
[45] B. Hyman,et al. Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy , 1995 .
[46] N. Inestrosa,et al. Platelets are the primary source of amyloid beta-peptide in human blood. , 1995, Biochemical and biophysical research communications.
[47] A D Roses,et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[48] J. Vonsattel,et al. Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study , 1991, Annals of neurology.
[49] J. Ubbink,et al. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. , 1991, Journal of chromatography.
[50] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.